A recent Actos bladder cancer lawsuit alleges that Takeda Pharmaceutical Co., the Osaka Japan-based maker of Actos and Asia’s largest pharmaceutical company, used deceptive practices to keep the drug on the market for as long as possible to maintain sales.
Court Documents Allege Takeda Secretly Surveyed Doctors
Court documents filed in a recent Actos bladder cancer lawsuit allege that Takeda Pharmaceuticals became concerned that its diabetes drug could be linked to cancer and secretly surveyed doctors to see if they would prescribe a drug that contained a warning of an increased risk of bladder cancer.
Although the company denies those allegations, court documents allege that the secret survey found that adding a bladder cancer warning would destroy Actos sales, according to a recent Bloomberg News article. Takeda did not add that warning until the FDA forced it to in 2010. Actos accounted for over $4 billion in sales for the company at that time.
Over 3,000 Actos Bladder Cancer Lawsuits Filed
Over 3,000 Actos bladder cancer lawsuits have been filed against Takeda already and more are likely. Many allege that the company:
- Manufactured and sold Actos without performing thorough and sufficient pre-market and post-market testing
- Willfully withheld information of the increased danger of developing bladder cancer
- Failed to warn of known risks.
The first Actos bladder cancer trial began this week – and if the allegations above are proven true, it’s not good news for Takeda.
Have You Been Diagnosed With Bladder Cancer?
If you’ve been diagnosed with bladder cancer after taking Actos, contact The Driscoll Firm, LLC, to review your situation and provide you with the information you need to make an informed decision about whether taking legal action against Takeda is in your best interests. Consultations are free and without obligation.
